| Mr Philip Veatch, MD | |
|
1908 Hilco St, Suite B, Suite B, Albemarle, NC 28001-6307 | |
| (704) 983-3855 | |
| (704) 985-1031 |
| Full Name | Mr Philip Veatch |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 35 Years |
| Location | 1908 Hilco St, Suite B, Albemarle, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174503718 | NPI | - | NPPES |
| 84978 | Other | NC | BLUE CROSS BLUE SHIELD |
| 110151715 | Other | RAILROAD MEDICARE | |
| 4633508 | Other | AETNA | |
| 890105E | Medicaid | NC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 35219 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Stanly County Home Health Agen | Albemarle, NC | Home health agency |
| Atrium Healt At Home Stanly | Albemarle, NC | Home health agency |
| Gentiva Health Services/salisb | Kannapolis, NC | Home health agency |
| Hospice Of Stanly County Inc | Albemarle, NC | Hospice |
| Stanly Regional Medical Center | Albemarle, NC | Hospital |
| Carolinas Medical Center-northeast | Concord, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Central Carolina Medical Associates Pa | 7416909825 | 3 |
News Archive
FibroGen, Inc., today announced that FibroGen and partner Astellas Pharma Inc. advanced FG-4592 (Astellas designation ASP1517), an investigational anemia therapy, to phase 2b development for treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis.
California State University San Marcos has earned initial accreditation from the Council on Academic Accreditation (CAA) of the American Speech-Language Hearing Association for the Master of Science in Speech-Language Pathology (SLP) program.
The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine at Yeshiva University a five-year, $5.9 million grant to develop a new vaccine against tuberculosis (TB), including the toughest-to-treat forms of the disease known as multi drug-resistant and extensively drug-resistant. The grant will build on a new approach to TB vaccine design that is based on genetically altered Mycobacterium smegmatis, which is closely related to the bacterial species (Mycobacterium tuberculosis) that causes TB in humans.
ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com ), a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP™) for medicine, biotechnology and cosmetic industries stated that it has repeatedly demonstrated the ability of their AAGP™ molecule to protect against the attacks of the most hostile inflammation causing agents known.
The National Institutes of Health (NIH) has awarded $3.2 million to a team of preeminent engineering, chemistry, and biology researchers to develop a highly efficient system of generating nucleic acid molecules, called aptamers.
› Verified 7 days ago
| Entity Name | Central Carolina Medical Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497735179 PECOS PAC ID: 7416909825 Enrollment ID: O20050214000920 |
News Archive
FibroGen, Inc., today announced that FibroGen and partner Astellas Pharma Inc. advanced FG-4592 (Astellas designation ASP1517), an investigational anemia therapy, to phase 2b development for treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis.
California State University San Marcos has earned initial accreditation from the Council on Academic Accreditation (CAA) of the American Speech-Language Hearing Association for the Master of Science in Speech-Language Pathology (SLP) program.
The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine at Yeshiva University a five-year, $5.9 million grant to develop a new vaccine against tuberculosis (TB), including the toughest-to-treat forms of the disease known as multi drug-resistant and extensively drug-resistant. The grant will build on a new approach to TB vaccine design that is based on genetically altered Mycobacterium smegmatis, which is closely related to the bacterial species (Mycobacterium tuberculosis) that causes TB in humans.
ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com ), a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP™) for medicine, biotechnology and cosmetic industries stated that it has repeatedly demonstrated the ability of their AAGP™ molecule to protect against the attacks of the most hostile inflammation causing agents known.
The National Institutes of Health (NIH) has awarded $3.2 million to a team of preeminent engineering, chemistry, and biology researchers to develop a highly efficient system of generating nucleic acid molecules, called aptamers.
› Verified 7 days ago
| Entity Name | Hospice Of Stanly County, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174124614 PECOS PAC ID: 0749328425 Enrollment ID: O20201210002186 |
News Archive
FibroGen, Inc., today announced that FibroGen and partner Astellas Pharma Inc. advanced FG-4592 (Astellas designation ASP1517), an investigational anemia therapy, to phase 2b development for treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis.
California State University San Marcos has earned initial accreditation from the Council on Academic Accreditation (CAA) of the American Speech-Language Hearing Association for the Master of Science in Speech-Language Pathology (SLP) program.
The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine at Yeshiva University a five-year, $5.9 million grant to develop a new vaccine against tuberculosis (TB), including the toughest-to-treat forms of the disease known as multi drug-resistant and extensively drug-resistant. The grant will build on a new approach to TB vaccine design that is based on genetically altered Mycobacterium smegmatis, which is closely related to the bacterial species (Mycobacterium tuberculosis) that causes TB in humans.
ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com ), a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP™) for medicine, biotechnology and cosmetic industries stated that it has repeatedly demonstrated the ability of their AAGP™ molecule to protect against the attacks of the most hostile inflammation causing agents known.
The National Institutes of Health (NIH) has awarded $3.2 million to a team of preeminent engineering, chemistry, and biology researchers to develop a highly efficient system of generating nucleic acid molecules, called aptamers.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Philip Veatch, MD 1908 Hilco St, Suite B, Albemarle, NC 28001-6307 Ph: (704) 983-3855 | Mr Philip Veatch, MD 1908 Hilco St, Suite B, Suite B, Albemarle, NC 28001-6307 Ph: (704) 983-3855 |
News Archive
FibroGen, Inc., today announced that FibroGen and partner Astellas Pharma Inc. advanced FG-4592 (Astellas designation ASP1517), an investigational anemia therapy, to phase 2b development for treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis.
California State University San Marcos has earned initial accreditation from the Council on Academic Accreditation (CAA) of the American Speech-Language Hearing Association for the Master of Science in Speech-Language Pathology (SLP) program.
The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine at Yeshiva University a five-year, $5.9 million grant to develop a new vaccine against tuberculosis (TB), including the toughest-to-treat forms of the disease known as multi drug-resistant and extensively drug-resistant. The grant will build on a new approach to TB vaccine design that is based on genetically altered Mycobacterium smegmatis, which is closely related to the bacterial species (Mycobacterium tuberculosis) that causes TB in humans.
ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com ), a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP™) for medicine, biotechnology and cosmetic industries stated that it has repeatedly demonstrated the ability of their AAGP™ molecule to protect against the attacks of the most hostile inflammation causing agents known.
The National Institutes of Health (NIH) has awarded $3.2 million to a team of preeminent engineering, chemistry, and biology researchers to develop a highly efficient system of generating nucleic acid molecules, called aptamers.
› Verified 7 days ago
Kushal C. Vaishnani, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 301 Yadkin St, Albemarle, NC 28001 Phone: 704-984-4365 | |
Douglas W Haden, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 301 Yadkin St, Albemarle, NC 28001 Phone: 704-984-4365 | |
Mr. Rufus Stamey Lefler Iii, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 923 North Second Street, Suite 101, Albemarle, NC 28001 Phone: 704-982-1136 Fax: 704-982-1139 | |
Souheil Abdel Nour, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 929 N 2nd St, Ste 205, Albemarle, NC 28001 Phone: 980-323-5625 | |
Sherry J. Saxonhouse, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 307 Yadkin St, Albemarle, NC 28001 Phone: 980-323-6180 | |
Christopher Sutton Poor, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 929 N 2nd St, Ste 205, Albemarle, NC 28001 Phone: 980-323-5625 |